2008;4:293 9. 282. Kakkar AK, Moustapha A, Hanley HG, et al. Comparison of intracoro- nary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv. 2004;61:31 4. 283. W hrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable an- gina undergoing coronary angioplasty. Circulation. 2003;107:1840 3. 284. Bertrand OF, Rod s-Cabau J, Larose E, et al. Intracoronary compared to intravenous abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction un- dergoing transradial primary percutaneous coronary intervention: a two- by-two factorial placebo-controlled randomized study. Am J Cardiol. 2010;105:1520 7. 285. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354 62. 286. Collet J-P, Hulot J-S, Pena A, et al. Cytochrome P450 2C19 polymor- phism in young patients treated with clopidogrel after myocardial infarc- tion: a cohort study. Lancet. 2009;373:309 17. 287. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of- function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30:916 22. 288. Giusti B, GoriAM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009;103:806 11. 289. Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clini- cal alert: approaches to the FDA boxed warning : a report of the Ameri- can College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010;122:537 57. 290. Par G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on out- comes of clopidogrel treatment. N Engl J Med. 2010;363:1704 14. 291. 